Free tool
FAERS Monitor: Tremfya
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761061 or its brand name (Tremfya, Guselkumab). Reports on generic versions are filed under their own applications.
Reports
38,224
Serious
9,624
25% of reports
Hospitalization
2,874
Death reported
482
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue12,395
- accidental exposure to product3,707
- drug ineffective2,587
- needle issue2,480
- psoriasis2,311
- device issue2,150
- device deployment issue1,793
- device malfunction1,772
- off label use1,650
- product storage error1,218
- device defective1,207
- inappropriate schedule of product administration1,118
- arthralgia1,040
- device leakage1,010
- product leakage993
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 84 |
| 2018 | 1,199 |
| 2019 | 2,087 |
| 2020 | 2,193 |
| 2021 | 3,115 |
| 2022 | 5,058 |
| 2023 | 5,778 |
| 2024 | 5,014 |
| 2025 | 6,820 |
| 2026 | 6,874 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,015,935 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product leakageSignal | 993 | 133.8 | 124.9 | 105,195 |
| device deployment issueSignal | 1,793 | 89.7 | 85.4 | 135,170 |
| needle issueSignal | 2,480 | 51.1 | 49.1 | 111,656 |
| device defectiveSignal | 1,207 | 41.1 | 38.8 | 43,947 |
| product dose omission issueSignal | 12,395 | 24.2 | 23.8 | 267,423 |
| accidental exposure to productSignal | 3,707 | 20.5 | 19.9 | 66,575 |
| device malfunctionSignal | 1,772 | 14.2 | 13.6 | 21,268 |
| device issueSignal | 2,150 | 13.5 | 12.9 | 24,360 |
| device leakageSignal | 1,010 | 13.1 | 12.3 | 11,036 |
| psoriasisSignal | 2,311 | 9.9 | 9.5 | 18,254 |
| product storage errorSignal | 1,218 | 7.7 | 7.3 | 7,084 |
| inappropriate schedule of product administrationSignal | 1,118 | 3.4 | 3.2 | 1,925 |
| arthralgia | 1,040 | 1.4 | 1.3 | 109 |
| drug ineffective | 2,587 | 1.1 | 1.0 | 16 |
| off label use | 1,650 | 1.0 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.